The PD-1/PD-L1/PD-L2 checkpoint pathway plays a critical role in regulation of T lymphocytes in cancer and its disruption has been manifested in the improved clinical outcome for cancer patients (7–10, 15–21). This evidence concerns the gene CD274 and cancer.